- BAUER David
- BEGHINI Marianna
- BEIGLBÖCK Hannes
- BERNER Carolin
- BRUSILOVSKAYA Ksenia
- CHROMY David
- DEISCHINGER Carola
- DIXON Emmanuel Dauda
- EPPEL Daniel
- FALCONE Veronica
- FEHER Balazs
- FELLINGER Paul
- FISCHER Arabella
- FÖSSLEITNER Philipp
- GERNER Marlene
- GISINGER Teresa
- HAGER Marlene
- HASENÖHRL Timothy
- HEDESAN Oana
- HEINZL Matthias
- HEROLD Alexander
- HERZ Carsten
- HOFER Benedikt
- KALTENECKER Christopher
- KOGLER Hubert
- KÖNIGSHOFER Philipp
- LEITNER Miriam Kristin
- METZ Matthäus
- PALMA Stefano
- PATEISKY Petra
- PAUNKOV Ana
- PERRICOS Alexandra
- PFISTERER Nikolaus
- POGLITSCH Marcus
- RANZENBERGER-HAIDER Tamara
- REISCHER Theresa
- ROZMARIC Tomaz
- SCHÄFER Bhavapriya
- SCHAUER Ingrid
- SCHEINER Bernhard
- SCHERR Stefan
- SCHMIDBAUER Caroline
- SIMBRUNNER Benedikt
- STAUFER Katharina
- STEINACHER Daniel
- AGHAZARIAN Artin
- THANHÄUSER Margarita
- Former Students
STEINACHER Daniel
Supervisor: Michael Trauner
Committee: Michael Krebs, Harald Esterbauer
Department: Internal Medicine III, Clinical Division of Hepatology
E-mail: daniel.steinacher@meduniwien.ac.at
Tel: +43 (0)1 40400 - 61590
Homepage: http://www.meduniwien.ac.at/innere3/
Current academic degree: Cand.med.
Previous University and Subject: Medical University of Vienna, Human Medicine
Thesis since: 10/2013
Characterization of Metabolic and Therapeutic Properties of Modified Bile Acid Derivatives
Prevalence of nonalcoholic fatty liver disease (NAFLD) - a spectrum of liver diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) leading to liver cirrhosis and hepatocellular carcinoma (HCC) - is increasing. Bile acids (BA) could constitute a new therapeutic option. BA can improve liver damages in a mouse model for liver diseases by stimulating biliary HCO3 secretion, reducing inflammation, fibrosis and apoptosis. Therefore, we want to investigate bile acids in mouse models of liver diseases.
Methods and Skills:
Western blot; histology; real time PCR; metabolic cages
